Bazelet signed a manufacturing and licensing agreement with Israeli medical cannabis pharmaceutical product developer Alvit LCS Pharma to manufacture, market, and sell Alvit's line of pharma grade medical cannabis products in Israel and the EU. These products include sublingual tablets, oral sprays, extended release, delayed release, and suppositories containing Bazelet's proprietary and patent-pending active pharmaceutical ingredient (API). Bazelet will manufacture the products in its recently completed, state of the art, fully GMP compliant manufacturing facility, and expects to begin marketing the products in the first half of 2019.
Bazelet and Alvit additionally signed a joint research and development agreement to develop a new pharmaceutical drug for the treatment of Inflammatory Bowel Disease (IBD) based on Bazelet's API. Alvit will be responsible for researching and developing a pharmaceutical product based on Alvit's unique drug delivery technologies and Bazelet's API.
"The addition of Alvit's medical cannabis product line to our other medical cannabis offerings further strengthens and fortifies Bazelet's already leading position in the Israeli Medical Cannabis market, and further expands our product offerings as we prepare to enter into the European marketplace,” Meir Ariel, CEO of Bazelet said. “These products are also a perfect complement to our direct to consumer distribution model, allowing us to directly educate consumers about the benefits of each product type."
"We have been developing our line of advanced medical cannabis products for the last 5 years and are excited to be partnering with the industry leader Bazelet to begin manufacturing and distributing our product line,” Yona levy, CEO of Alvit said. “We already have several products undergoing clinical trials and this agreement was a natural next step for our company. We look forward to working with Bazelet to both manufacture and distribute our products, and to research and develop an IBD product based on Bazelet's unique API."